245 related articles for article (PubMed ID: 31313971)
1. Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application.
Singh OP; Gedda MR; Mudavath SL; Srivastava ON; Sundar S
Nanomedicine (Lond); 2019 Jul; 14(14):1911-1927. PubMed ID: 31313971
[TBL] [Abstract][Full Text] [Related]
2. A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis-an experimental study.
Joshi J; Malla N; Kaur S
Parasitol Int; 2014 Aug; 63(4):612-20. PubMed ID: 24747611
[TBL] [Abstract][Full Text] [Related]
3. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
4. Hemophagocytic lymphohistiocytosis associated with visceral leishmaniasis.
Matnani R; Ganapathi KA
Blood; 2016 Jan; 127(4):513. PubMed ID: 27218126
[No Abstract] [Full Text] [Related]
5. Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.
Kumar A; Singh VK; Tiwari R; Madhukar P; Rajneesh ; Kumar S; Gautam V; Engwerda C; Sundar S; Kumar R
Front Immunol; 2023; 14():1236952. PubMed ID: 37638047
[TBL] [Abstract][Full Text] [Related]
6. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
7. Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence.
Sundar S; Singh OP; Chakravarty J
Expert Rev Anti Infect Ther; 2018 Nov; 16(11):805-812. PubMed ID: 30289007
[TBL] [Abstract][Full Text] [Related]
8. Host resistance to visceral leishmaniasis: prevalence and prevention.
Maran N; Gomes PS; Freire-de-Lima L; Freitas EO; Freire-de-Lima CG; Morrot A
Expert Rev Anti Infect Ther; 2016; 14(4):435-42. PubMed ID: 26934623
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the diagnosis and treatment of kala-azar.
Sundar S; Chakravarty J
Natl Med J India; 2012; 25(2):85-9. PubMed ID: 22686715
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of artemisinin-loaded nanoparticles in experimental visceral leishmaniasis.
Want MY; Islamuddin M; Chouhan G; Ozbak HA; Hemeg HA; Dasgupta AK; Chattopadhyay AP; Afrin F
Colloids Surf B Biointerfaces; 2015 Jun; 130():215-21. PubMed ID: 25936561
[TBL] [Abstract][Full Text] [Related]
11. Nanodiagnostics in leishmaniasis: A new frontiers for early elimination.
Gedda MR; Madhukar P; Shukla A; Mudavath SL; Srivastava ON; Singh OP; Sundar S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Mar; 13(2):e1675. PubMed ID: 33142369
[TBL] [Abstract][Full Text] [Related]
12. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
13. Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis.
Varma DM; Redding EA; Bachelder EM; Ainslie KM
ACS Biomater Sci Eng; 2021 May; 7(5):1725-1741. PubMed ID: 33966377
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis.
Tyagi R; Lala S; Verma AK; Nandy AK; Mahato SB; Maitra A; Basu MK
J Drug Target; 2005 Apr; 13(3):161-71. PubMed ID: 16036304
[TBL] [Abstract][Full Text] [Related]
15. A spotlight on the diagnostic methods of a fatal disease Visceral Leishmaniasis.
Kumar A; Pandey SC; Samant M
Parasite Immunol; 2020 Oct; 42(10):e12727. PubMed ID: 32378226
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicines for Therapy of Visceral Leishmaniasis.
Want MY; Yadav P; Afrin F
J Nanosci Nanotechnol; 2016 Mar; 16(3):2143-51. PubMed ID: 27455613
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive Diagnosis of Visceral Leishmaniasis: Development and Evaluation of Two Urine-Based Immunoassays for Detection of Leishmania donovani Infection in India.
Ejazi SA; Bhattacharya P; Bakhteyar MA; Mumtaz AA; Pandey K; Das VN; Das P; Rahaman M; Goswami RP; Ali N
PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005035. PubMed ID: 27741241
[TBL] [Abstract][Full Text] [Related]
18. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.
Mishra J; Madhubala R; Singh S
Parasitol Res; 2013 Mar; 112(3):1001-9. PubMed ID: 23242321
[TBL] [Abstract][Full Text] [Related]
19. Molecular Diagnosis of Visceral Leishmaniasis.
Sundar S; Singh OP
Mol Diagn Ther; 2018 Aug; 22(4):443-457. PubMed ID: 29922885
[TBL] [Abstract][Full Text] [Related]
20. Emergence of visceral leishmaniasis in Sri Lanka: a newly established health threat.
Siriwardana HVYD; Karunanayake P; Goonerathne L; Karunaweera ND
Pathog Glob Health; 2017 Sep; 111(6):317-326. PubMed ID: 28820339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
